Terms: = Breast cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Clinical Outcome
6 results:
1. Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies.
Dermawan JK; Chi P; Tap WD; Rosenbaum E; D'Angelo S; Alektiar KM; Antonescu CR
J Pathol; 2023 Aug; 260(4):465-477. PubMed ID: 37350195
[TBL] [Abstract] [Full Text] [Related]
2. Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness.
Dhakal HP; Naume B; Synnestvedt M; Borgen E; Kaaresen R; Schlichting E; Wiedswang G; Bassarova A; Holm R; Giercksky KE; Nesland JM
Histopathology; 2012 Sep; 61(3):350-64. PubMed ID: 22690749
[TBL] [Abstract] [Full Text] [Related]
3. p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
Yang SX; Steinberg SM; Nguyen D; Swain SM
Int J Oncol; 2011 May; 38(5):1445-52. PubMed ID: 21399868
[TBL] [Abstract] [Full Text] [Related]
4. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract] [Full Text] [Related]
5. ERK phosphorylation is linked to vegfr2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis.
Svensson S; Jirström K; Rydén L; Roos G; Emdin S; Ostrowski MC; Landberg G
Oncogene; 2005 Jun; 24(27):4370-9. PubMed ID: 15806151
[TBL] [Abstract] [Full Text] [Related]
6. Tumor-specific VEGF-A and vegfr2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
[TBL] [Abstract] [Full Text] [Related]
